ChemGenex Pharmaceuticals clinical trials
Acquired by Teva Pharmaceutical Industries, Ltd., Oct 14, 2011 · source ↗
The registry lists 2 studies whose lead sponsor is ChemGenex Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 15, 2015.
- 2studies on the registry
- 0open to participants now
Before and after it joined Teva Pharmaceutical Industries, Ltd.
- First submitted before ChemGenex Pharmaceuticals became part of Teva Pharmaceutical Industries, Ltd.
- 2
- First submitted after ChemGenex Pharmaceuticals became part of Teva Pharmaceutical Industries, Ltd.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs ChemGenex Pharmaceuticals’ studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 2
All 2 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 108
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 1 started before 2008. 2026 so far in the lighter column.
Registry sponsor names on this page
- ChemGenex Pharmaceuticals2 studies
Something wrong with this grouping? Tell us on the Teva Pharmaceutical Industries, Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All Teva Pharmaceutical Industries, Ltd. studies →
- Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)TerminatedNCT00114959Phase 2
Sponsor listed in the registry: ChemGenex Pharmaceuticals · First submitted before ChemGenex Pharmaceuticals became part of Teva Pharmaceutical Industries, Ltd.
- Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic TumorsCompletedNCT00675350Phase 1
Sponsor listed in the registry: ChemGenex Pharmaceuticals · First submitted before ChemGenex Pharmaceuticals became part of Teva Pharmaceutical Industries, Ltd.